Small Molecules

07 Jan 2019 Galapagos starts first Phase 1 trial with Toledo compound
05 Jan 2019 BerGenBio Announces Start of Phase II Investigator Initiated Trial Evaluating Selective AXL Inhibitor Bemcentinib in High-risk MDS
05 Jan 2019 ASLAN Pharmaceuticals Announces IND Submission for ASLAN003 to U.S. FDA and Conclusion of 30-Day Review Period
05 Jan 2019 Arvinas Receives Authorization to Proceed for its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer
03 Jan 2019 Mavupharma Selects First Immuno-Oncology Clinical Candidate MAVU-104, an Oral STING Pathway Enhancer
03 Jan 2019 Pliant Therapeutics Initiates Phase 1 Clinical Study of PLN-74809
03 Jan 2019 Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata
03 Jan 2019 Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Carboplatin in Patients with Advanced or Metastatic Solid Tumors
03 Jan 2019 Urovant Sciences Initiates Patient Enrollment in Phase 2a Clinical Trial for Vibegron in Patients with Abdominal Pain Due to Irritable Bowel Syndrome
03 Jan 2019 Deciphera Pharmaceuticals Announces Positive, Preliminary, Top-Line Clinical Data for the Ongoing Phase 1 Clinical Study with DCC-3014 and an Update on Future Development Plans
03 Jan 2019 Bristol-Myers Squibb’s Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
03 Jan 2019 Adlai Nortye Announces Clinical Collaboration with Merck to Evaluate Adlai Nortye's AN0025 (EP4 Antagonist) in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
03 Jan 2019 BioCryst Initiates Phase 1 Clinical Trial of Galidesivir
03 Jan 2019 MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi
03 Jan 2019 Flexion Therapeutics Enrolls First Patient in Phase 3 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Hip and Reports Results from SHIP Study
03 Jan 2019 Cybrexa Therapeutics Selects Lead Clinical Candidate CBX-11, Combining its alphalex™ Technology with an Approved PARP Inhibitor to Treat Various Solid Tumors in Combination with Chemotherapy
27 Dec 2018 Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy
27 Dec 2018 Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the U.S. Food and Drug Administration
27 Dec 2018 Acer Therapeutics Announces FDA Acceptance of NDA and Priority Review for EDSIVO™ for the Treatment of vEDS
21 Dec 2018 Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305
21 Dec 2018 Foamix Submits New Drug Application to U.S. FDA Seeking Approval of FMX101 in Treatment of Moderate-to-Severe Acne
21 Dec 2018 Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program for Ruxolitinib Cream in Atopic Dermatitis
21 Dec 2018 Lynparza meets primary endpoint in Phase III SOLO-3 trial for the treatment of relapsed BRCA-mutated advanced ovarian cancer
21 Dec 2018 Acorda Therapeutics Announces FDA Approval of INBRIJA™ (levodopa inhalation powder)
20 Dec 2018 Supernus Announces Positive Results from Phase III Study For SPN-812 in Adolescents with ADHD

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up